Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
INVESTOR PRESENTATION - Immutep Limited
Health
Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
announcement | t+2 movement | date |
---|---|---|
| +3.70% | 06 Jan 2021 |
| -2.41% | 04 Jan 2021 |
| -2.41% | 03 Jan 2021 |
| 0.00% | 31 Dec 2020 |
| -1.19% | 30 Dec 2020 |
| +6.41% | 29 Dec 2020 |
| +6.41% | 29 Dec 2020 |
| +6.41% | 28 Dec 2020 |
| +7.69% | 24 Dec 2020 |
| +7.69% | 24 Dec 2020 |
Current Price
52WK HIGH
52WK LOW
1YR RETURN
1YR RETURN VS. SECTOR
90 DAY RETURN
ASX RANK
/2,047
SECTOR RANK
/168
SHARES OUTSTANDING
Health
Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
ASX:IMM is not raising right now
Want to invest?
(03) 9028 2888
clients@freshequities.com
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia